Bio-Techne Corporation (TECH) Income Statement

The sequential revenue trajectory from 2025Q4 to 2026Q4 shows a pattern of stabilization after a period of contraction, with the company returning to modest positive growth. This deceleration appears consistent with the broader industry trend of cautious biotech capital spending, which typically impacts instrument placements before reagent consumption. The durability of this recovery remains uncertain, as the lack of forward guidance and persistent China volatility suggest the growth inflection may be fragile.

The divergence between the stable, high gross margin and the volatile operating margin suggests that the company's cost structure has become less efficient. The significant jump in SG&A from $23.2M in 2025Q4 to over $110M in recent quarters appears to be the primary driver, potentially reflecting the full integration of prior acquisitions or increased commercial investment. This margin profile warrants monitoring to determine if it represents a temporary investment phase or a new, lower-margin operating reality.

The data indicates that incremental revenue is not flowing through to the bottom line at historical rates. The primary culprit appears to be elevated SG&A expenses, which have remained above $109M in each of the last four quarters, compared to a low of $23.2M in 2025Q4. This suggests that the company's overhead structure has expanded, possibly due to M&A integration or strategic investments, and may be constraining profitability until revenue growth accelerates further.

The dramatic shift in SG&A as a percentage of revenue is the most notable feature of the recent cost structure. This could indicate a normalization of expenses after a period of unusual accounting treatment, or it may reflect a structural increase in sales, general, and administrative overhead. The stability of R&D spending around $23-24M per quarter suggests management is maintaining its innovation investment, but the SG&A trend is the key variable for future margin recovery.